Attached files
| file | filename |
|---|---|
| 10-K - LIGHTLAKE THERAPEUTICS, INC. 10-K - OPIANT PHARMACEUTICALS, INC. | a6074458.htm |
| EX-3.I - EXHIBIT 3 - OPIANT PHARMACEUTICALS, INC. | a6074458ex3i.htm |
| EX-31.2 - EXHIBIT 31.2 - OPIANT PHARMACEUTICALS, INC. | a6074458ex31_2.htm |
| EX-10.6 - EXHIBIT 10-6 - OPIANT PHARMACEUTICALS, INC. | a6074458ex10_6.htm |
| EX-10.7 - EXHIBIT 10-7 - OPIANT PHARMACEUTICALS, INC. | a6074458ex10_7.htm |
| EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC. | a6074458ex31_1.htm |
| EX-10.5 - EXHIBIT 10-5 - OPIANT PHARMACEUTICALS, INC. | a6074458ex10_5.htm |
| EX-10.4 - EXHIBIT 10-4 - OPIANT PHARMACEUTICALS, INC. | a6074458ex10_4.htm |
EXHIBIT
32
CERTIFICATION
Pursuant
to 18 U.S.C. 1350
(Section
906 of the Sarbanes-Oxley Act of 2002)
In
connection with the Annual Report on Form 10-K of Lightlake Therapeutics Inc.
(the"Company") for the year ended July 31, 2008, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), Seijin Ki, as
ChiefExecutive Officer and Chief Financial Officer of the Company, hereby
certifies, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the
Sarbanes-Oxley Act of 2002, that:
(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and
(2) The
information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.
|
Date:
10/15/09
|
By:
|
/s/ Seijin Ki | |
| Seijin Ki | |||
| Chief Executive Officer | |||
| Chief Financial Officer |
This
certification accompanies each Report pursuant to ss. 906 of the Sarbanes-Oxley
Act of 2002 and shalL not, except to the extent required by the Sarbanes-Oxley
Act of 2002, be deemed filed by the Company for purposes of ss.18 of the
Securities Exchange Act of 1934, as amended.
A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.